Based at the University of Edinburgh Professor Mark Bradley is a chemist by training but with a strong interdisciplinary ethos and translational mind set (for example he spent two years (1989-1991) at Harvard Medical School working the area of protein engineering and site directed mutagenesis).

He began his academic career in 1992 at the University of Southampton as a Royal Society University Research Fellow, where he worked in the area of Combinatorial Chemistry, co-founding Ilika Technologies. He moved to the University of Edinburgh in 2005 and over the years he was co-founder of Edinburgh Molecular Imaging, DestiNA Genomics and most recently BioCaptiva. He has published some 400 papers and reviews and 25 patents, is an ERC Advanced grant awardee and has won numerous prizes and awards e.g. Fellowship of the Royal Society of Edinburgh (FRSE), Fellowship of the Royal Society of Chemistry (FRSC), 2019 RSC Interdisciplinary prize and the University of Edinburgh Chancellors Award.

He is the formal PI on the EPSRC supported InLighenUs project and heads the Edinburgh team that encompasses areas of detectors, chemistry and engagement in its broadest senses.